Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Impact of Intravenous Administration of ACMP (Eptinezumab) on the Treatment of Atypical Resistant Facial Pain

NCT07250984 is registered in ClinicalTrials.gov with Alenka Spindler-Vesel as lead sponsor.

NCT NCT07250984
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07250984 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Impact of Intravenous Administration of ACMP (Eptinezumab) on the Treatment of Atypical Resistant Facial Pain
Lead sponsor
Alenka Spindler-Vesel
Phase
Observational
Overall status
Enrolling by invitation
Start date
November 3, 2025
Completion date
December 3, 2026
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

facial pain